Navigation Links
Exelixis Announces May 13 Webcast of Presentation at the Bank of America Health Care Conference
Date:5/8/2008

SOUTH SAN FRANCISCO, Calif., May 8 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) announced today that George A. Scangos, PhD, president and chief executive officer of Exelixis, will present at the Bank of America 2008 Health Care Conference at 11:40 a.m. ET/8:40 a.m. PT on Tuesday, May 13, 2008. Dr. Scangos will discuss updates to the company's development pipeline and corporate strategy.

The presentation will be webcast and may be accessed in the Event Calendar page under Investors on the Exelixis website at http://www.exelixis.com.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.


'/>"/>
SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Exelixis Announces May 6 Webcast of Its First Quarter 2008 Financial Results and Business Update Conference Call
2. Exelixis Announces April 30 Webcast of Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
3. Seven Abstracts Featuring Exelixis Compounds Accepted for Presentation at 2008 ASCO Annual Meeting
4. Option to Develop Exelixis Compound Exercised By Genentech
5. Exelixis Announces March 17 Webcast of Presentation at the Cowen and Company Annual Health Care Conference
6. Exelixis Announces March 4 Webcast of Presentation at the Susquehanna SIGnificant Options in Healthcare Conference
7. Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results
8. Exelixis Announces February 14 Webcast of Its Fourth Quarter and Full Year 2007 Financial Results Conference Call
9. Exelixis Announces February 12 Webcast of Presentation at the 10th Annual BIO CEO and Investor Conference
10. Exelixis Announces January 31 Webcast of Presentation at the 2008 Wachovia Healthcare Conference
11. Exelixis Announces Senior Management Promotions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014  Decision Resources Group finds that ... in the United States ... penetration will be the level of savings achievable ... expected lower cost to patients. Payers plan to ... their pricing expectations in order to encourage physician ...
(Date:7/30/2014)... 2014  Replikins Ltd. today released new data on ... Before the current outbreaks, the mean Ebola Reston gene ... between 1995 and 2002 was 1.1; the mean Replikin ... sixteen-fold in 2013, thus predicting the current outbreaks in ... been shown to be able to predict outbreaks (1). ...
(Date:7/30/2014)... AZ (PRWEB) July 30, 2014 Sales ... the launch of blended sales training programs for companies ... sales training programs used by thousands of salespeople over ... blended sales training program can be customized to address ... , The blended sales training program consists ...
(Date:7/30/2014)... NY (PRWEB) July 30, 2014 July ... (Twitter: @APDN), a biotechnology firm that provides DNA-based authentication ... E. Hogan, Ph.D. Vice President of Life Sciences, a ... , Dr. Hogan will lead APDN’s drive ... business relationships with biotech and healthcare customers, provide guidance ...
Breaking Biology Technology:Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 2Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 3Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 3
... Ash ... the company is in the initial phases of a multi-year $6 million expansion project ... located in Riverview, Michigan. Expansions will include a new reactor bay and warehouse. ... Detroit, MI (PRWEB) ...
... Sept. 30 InteKrin Therapeutics Inc. announced today positive results ... the 45th European Association for the Study of Diabetes ... data will be presented at 1:45 PM Friday, October 2, ... His presentation is entitled "Impact of INT131 Besylate, a ...
... September 30 , - 76% ... Glycemic Control Versus Lantus(R) , Sanofi-aventis ... of a,head-to-head study providing further evidence on the efficacy of ... insulin detemir. The study was presented during the 45th,Annual Meeting ...
Cached Biology Technology:Ash Stevens Plans $6 Million Facility Expansion to Bolster CMC Capabilities 2InteKrin Therapeutics Presents Positive INT131 Phase 2b Results at the 45th Annual European Association for the Study of Diabetes Meeting 2Superior Efficacy-dose Ratio for Lantus(R) Over detemir 2Superior Efficacy-dose Ratio for Lantus(R) Over detemir 3Superior Efficacy-dose Ratio for Lantus(R) Over detemir 4Superior Efficacy-dose Ratio for Lantus(R) Over detemir 5
(Date:7/30/2014)... University,s College of Engineering recently received a $330,000 ... project, "Nanoparticle-directed synthesis of organic nanorods." , ... the creation and utilization of functional materials, devices, ... major bottleneck in scaling up nanotechnology is the ... materials into one device. A research team led ...
(Date:7/30/2014)... injury (SCI), traumatic brain injury (TBI) and peripheral nerve ... learned over the past 30 years regarding both the ... growth, but this large body of information has not ... his team from University of Miami in USA proposed ... consensus is emerging that one contributing factor is a ...
(Date:7/30/2014)... Washington, DCToday scientists unveiled the first high-resolution map ... the entire country of Per. The new and ... a sea change for future market-based carbon economies. ... extremely high ecological diversity and it provides the ... degradation for conservation, land use, and enforcement purposes. ...
Breaking Biology News(10 mins):NSF grant to Wayne State supports new concept for manufacturing nanoscale devices 2Peru's carbon quantified: Economic and conservation boon 2Peru's carbon quantified: Economic and conservation boon 3
... to promote interdisciplinary research that addresses complex interactions ... in recent years, but success is often elusive. ... social scientists attempting such work, Eric D. Roy ... a variety of institutions surveyed researchers at all ...
... MADISON, Wis. By any measure, tuberculosis (TB) is a wildly ... every corner of the world, with a new infection of a ... a new analysis of dozens of tuberculosis genomes gathered from around ... TB is so prevalent and how it evolves to resist countermeasures. ...
... August 2013 Metals such as iron, copper, and ... years, studies have shown that these nutritionally-essential metals are ... animal models of AD. Scientists are now exploring whether ... or are indicative of other ongoing pathologic processes. ...
Cached Biology News:Survey highlights barriers to interdisciplinary environmental science 2Tuberculosis genomes portray secrets of pathogen's success 2Elevated levels of copper in amyloid plaques associated with neurodegeneration in mouse models of AD 2
... (1995) This volume provides excellent ... for the study of major HIV proteins ... ribonuclease H, integrase and protease. Expression of ... Tat and Rev assays; HIV/CD4 interactions; transient ...
Monkey IL-2 ELISPOT Kit with white/opague microtiter plates...
Tachykinin (H-2)...
Human GATA-2 Affinity Purified Polyclonal Ab...
Biology Products: